Barclays lowered the firm’s price target on Collegium Pharmaceutical (COLL) to $56 from $58 and keeps an Overweight rating on the shares. The firm updated the company’s’ estimates to reflect its initial fiscal 2026 outlook.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical price target raised to $60 from $46 at H.C. Wainwright
- Collegium Pharmaceutical: Strengthened 2026 Outlook, Balance Sheet Flexibility, and BD Upside Support Buy Rating and Higher Target
- Collegium Issues 2026 Guidance Emphasizing Jornay PM Growth
- Collegium Pharmaceutical sees FY26 produce revenue $805M-$825M
- Collegium Pharmaceutical price target raised to $55 from $47 at Truist